During the past decade, Hospital Universitario Reina Sofia conducted 435 clinical trials. In the 10-year time frame, 435 clinical trials started and 129 clinical trials were completed, i.e. on average, 29.7% percent of trials that started reached the finish line to date. In the past 5 years, 218 clinical trials started and 90 clinical trials were completed. i.e. 41.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Universitario Reina Sofia" #1 sponsor was "Hoffmann-La Roche" with 38 trials, followed by "Maimónides Biomedical Research Institute of Córdoba" with 29 trials sponsored, "PETHEMA Foundation" with 26 trials sponsored, "Pfizer" with 25 trials sponsored and "Celgene" with 25 trials sponsored. Other sponsors include 462 different institutions and companies that sponsored additional 232 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Universitario Reina Sofia" #1 collaborator was "Pfizer" with 13 trials as a collaborator, "Eli Lilly and Company" with 10 trials as a collaborator, "Hospital Universitario Reina Sofia de Cordoba" with 10 trials as a collaborator, "Merck Sharp & Dohme LLC" with 10 trials as a collaborator and "Hoffmann-La Roche" with 9 trials as a collaborator. Other collaborators include 411 different institutions and companies that were collaborators in the rest 267 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Universitario Reina Sofia" are "Breast Cancer" (30 trials), "Ovarian Cancer" (14 trials), "HIV Infections" (11 trials), "Ulcerative Colitis" (10 trials) and "Crohn Disease" (9 trials). Many other conditions were trialed in "Hospital Universitario Reina Sofia" in a lesser frequency.

Most popular intervention types in "Hospital Universitario Reina Sofia" are "Drug" (420 trials), "Other" (82 trials), "Biological" (40 trials), "Device" (32 trials) and "Procedure" (27 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (112 trials), "Paclitaxel" (23 trials), "Carboplatin" (19 trials), "Docetaxel" (17 trials) and "Atezolizumab" (16 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Universitario Reina Sofia" are 517 trials for "All" genders, 61 trials for "Female" genders and 24 trials for "Male" genders.

Currently, there are 216 active trials in "Hospital Universitario Reina Sofia". 4 are not yet recruiting, 121 are recruiting, 89 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 287 completed trials in Hospital Universitario Reina Sofia, 2 suspended trials, and 58 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Universitario Reina Sofia, 26 "Phase 1" clinical trials were conducted, 148 "Phase 2" clinical trials and 246 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 49 trials, and there were also 50 trials that are defined as “Not Applicable".